{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:04:23Z","timestamp":1772449463926,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In patients with chronic liver diseases such as cirrhosis, massive ascites after hepatic resection is the cause of prolonged hospitalization and worsening prognosis. Recently, the efficacy of tolvaptan in refractory ascites has been reported; however, there are no reports on the efficacy or safety of tolvaptan for refractory ascites after hepatic resection. This study aims to evaluate the efficacy of early administration of tolvaptan in patients with refractory ascites after hepatic resection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods:<\/jats:title>\n            <jats:p>This is an open-label, single-arm phase I\/II study. This study subject will comprise patients scheduled for hepatic resection of a liver tumor. Patients with refractory ascites after hepatic resection (drainage volume on postoperative day 1 \u22655\u00a0ml\/body weight 1\u00a0kg\/day) will be treated with tolvaptan. The primary endpoint will include the maximum change in body weight after hepatic resection relative to the preoperative baseline. The secondary endpoints will include drainage volume, abdominal circumference, urine output, postoperative complication rate (heart failure and respiratory failure), number of days required for postoperative weight gain because of ascites to decrease to preoperative weight, change in improvement of postoperative pleural effusion, total amount of albumin or fresh frozen plasma transfusion, type and amount of diuretics used, and postoperative hospitalization days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This trial will evaluate the efficacy and safety of tolvaptan prophylaxis for refractory ascites after hepatic resection. As there are no reports demonstrating the efficacy of tolvaptan prophylaxis for refractory ascites after hepatic resection, the authors expect that these findings will lead to future phase III trials and provide valuable indications for the selection of treatments for refractory postoperative ascites.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/sp9.0000000000000015","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T13:08:58Z","timestamp":1702991338000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Protocol to evaluate the efficacy and safety of tolvaptan in patients with refractory ascites after liver resection: an open-label, single-arm phase I\/II study"],"prefix":"10.1097","volume":"28","author":[{"given":"Yosuke","family":"Namba","sequence":"first","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"},{"name":"Department of Gastroenterological-Breast and Transplant Surgery, Hiroshima Prefectural Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"},{"name":"Department of Surgery and Endoscopic Surgery, JA Onomichi General Hospital, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotaro","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Oshita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiso","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruhiko","family":"Honmyo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tahara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ohira","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ide","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ohdan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,3]]},"reference":[{"key":"R1-20250825","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archsurg.2008.511","article-title":"Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma","volume":"144","author":"Ishizawa","year":"2009","journal-title":"Arch Surg"},{"key":"R2-20250825","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s13304-020-00733-6","article-title":"Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience","volume":"72","author":"Famularo","year":"2020","journal-title":"Updates Surg"},{"key":"R3-20250825","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1245\/s10434-016-5348-3","article-title":"A randomized clinical trial of preoperative administration of branched-chain amino acids to prevent postoperative ascites in patients with liver resection for hepatocellular carcinoma","volume":"23","author":"Kikuchi","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R4-20250825","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3748\/wjg.v17.i10.1237","article-title":"Diagnosis and therapy of ascites in liver cirrhosis","volume":"17","author":"Biecker","year":"2011","journal-title":"World J Gastroenterol"},{"key":"R5-20250825","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1245\/s10434-009-0721-0","article-title":"Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas","volume":"16","author":"Itoh","year":"2009","journal-title":"Annals Surg Oncol"},{"key":"R6-20250825","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.21873\/anticanres.11459","article-title":"Post-hepatectomy refractory ascites in cirrhotic patients with hepatocellular carcinoma: risk factor analysis to overcome this problematic complication","volume":"37","author":"Itoh","year":"2017","journal-title":"Anticancer Res"},{"key":"R7-20250825","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jamasurg.2016.1121","article-title":"Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma","volume":"151","author":"Citterio","year":"2016","journal-title":"JAMA Surg"},{"key":"R8-20250825","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00268-017-4003-x","article-title":"Risk factors for postoperative ascites in patients undergoing liver resection for hepatocellular carcinoma","volume":"41","author":"Yoshikawa","year":"2017","journal-title":"World J Surg"},{"key":"R9-20250825","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12029-015-9701-8","article-title":"Small-for-size liver syndrome: a case series with a proposal for management based on portal flow modulation","volume":"46","author":"Famularo","year":"2015","journal-title":"J Gastrointest Cancer"},{"key":"R10-20250825","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s11605-021-04952-z","article-title":"The impact of postoperative ascites on survival after surgery for hepatocellular carcinoma: a national study","volume":"25","author":"Famularo","year":"2021","journal-title":"J Gastrointest Surg"},{"key":"R11-20250825","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc13991","article-title":"Albumin administration in the acutely ill: what is new and where next?","volume":"18","author":"Vincent","year":"2014","journal-title":"Crit Care"},{"key":"R12-20250825","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","article-title":"Evidence-based clinical practice guidelines for Liver Cirrhosis 2020","volume":"56","author":"Yoshiji","year":"2021","journal-title":"J Gastroenterol"},{"key":"R13-20250825","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.26359","article-title":"Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012","volume":"57","author":"Runyon","year":"2013","journal-title":"Hepatology"},{"key":"R14-20250825","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jacc.2020.12.057","article-title":"Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function","volume":"77","author":"Beldhuis","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R15-20250825","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/hepr.12195","article-title":"Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites","volume":"44","author":"Taki","year":"2014","journal-title":"Hepatol Res"},{"key":"R16-20250825","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/1744-9987.12469","article-title":"Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis","volume":"20","author":"Kozaki","year":"2016","journal-title":"Ther Apher Dial"},{"key":"R17-20250825","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2169\/internalmedicine.0629-17","article-title":"Association between the serum sodium levels and the response to tolvaptan in liver cirrhosis patients with ascites and hyponatremia","volume":"57","author":"Hayashi","year":"2018","journal-title":"Intern Med"},{"key":"R18-20250825","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hepr.12098","article-title":"Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"44","author":"Sakaida","year":"2014","journal-title":"Hepatol Res"},{"key":"R19-20250825","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hepr.12099","article-title":"Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: a randomized, double-blind, placebo-controlled trial","volume":"44","author":"Okita","year":"2014","journal-title":"Hepatol Res"},{"key":"R20-20250825","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/jgh.14047","article-title":"Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema","volume":"33","author":"Atsukawa","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"R21-20250825","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1097\/MEG.0000000000001985","article-title":"Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinomam","volume":"33","author":"Imai","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R22-20250825","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/hepr.13337","article-title":"Effect of tolvaptan on the prognosis of patients with hepatic ascites","volume":"49","author":"Hiramine","year":"2019","journal-title":"Hepatol Res"},{"key":"R23-20250825","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000503559","article-title":"Tolvaptan response improves overall survival in patients with refractory ascites: a meta-analysis","volume":"38","author":"Bellos","year":"2020","journal-title":"Dig Dis"},{"key":"R24-20250825","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40261-018-0714-5","article-title":"Impaired renal function may not negate the efficacy of tolvaptan in the treatment of cirrhotic patients with refractory ascites","volume":"39","author":"Arase","year":"2019","journal-title":"Clin Drug Investig"},{"key":"R25-20250825","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00535-020-01727-2","article-title":"Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites","volume":"56","author":"Hiramine","year":"2021","journal-title":"J Gastroenterol"},{"key":"R26-20250825","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"key":"R27-20250825","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/jcm3041276","article-title":"Review of tolvaptan\u2019s pharmacokinetic and pharmacodynamic properties and drug interactions","volume":"3","author":"Bhatt","year":"2014","journal-title":"J Clin Med"},{"key":"R28-20250825","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1253\/circj.CJ-16-1122","article-title":"Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction- prospective randomized controlled study","volume":"81","author":"Tamaki","year":"2017","journal-title":"Circ J"},{"key":"R29-20250825","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00380-018-1270-x","article-title":"Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR","volume":"34","author":"Ikeda","year":"2019","journal-title":"Heart Vessels"},{"key":"R30-20250825","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12872-017-0598-y","article-title":"Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"R31-20250825","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12872-023-03125-x","article-title":"Efficacy of tolvaptan in postoperative volume therapy for acute Stanford type A aortic dissection","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"R32-20250825","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/17474124.2014.903797","article-title":"Tolvaptan for the treatment of liver cirrhosis oedema","volume":"8","author":"Sakaida","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R33-20250825","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00535-016-1216-y","article-title":"Evidence-based clinical practice guidelines for liver cirrhosis 2015","volume":"51","author":"Fukui","year":"2016","journal-title":"J Gastroenterol"},{"key":"R34-20250825","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure in cirrhosis","volume":"36","author":"Gin\u00e8s","year":"2009","journal-title":"N Engl J Med"}],"container-title":["International Journal of Surgery Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SP9.0000000000000015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T22:00:35Z","timestamp":1756159235000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SP9.0000000000000015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/sp9.0000000000000015","relation":{},"ISSN":["2468-3574"],"issn-type":[{"value":"2468-3574","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"2023-06-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}